Liarozole: A Novel Treatment Approach for Advanced Prostate Cancer - Results of a Large Randomized Trial Versus Cyproterone Acetate

    July 1998 in “ Urology ”
    F. Debruyne, Robin Murray, Yves Fradet, Jan Johansson, C.J. Tyrrell, Francesco Boccardo, L. Denis, J. Marberger, D. Brune, Jens Rassweiler, Tony Vangeneugden, J. Bruynseels, Monique Janssens, Peter De Porre
    TLDR Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
    The study compared the efficacy of liarozole, a retinoic acid metabolism-blocking agent, with cyproterone acetate (CPA) in 321 patients with metastatic prostate cancer who had relapsed after first-line endocrine therapy. Liarozole showed a 26% lower risk of death compared to CPA (P = 0.039) and a higher prostate-specific antigen (PSA) response rate (20% vs. 4%, P < 0.001). PSA responders had a median survival benefit of 10 months over nonresponders. Pain and quality of life improved more in the liarozole group. Adverse events in the liarozole group were generally mild to moderate. The study concluded that liarozole was superior to CPA in terms of PSA response, PSA progression, and survival, while maintaining patients' quality of life.
    Discuss this study in the Community →